logo-bm-390x140

The Biosimilar Medicines Group represents the leading companies developing, manufacturing and marketing biosimilar medicines across Europe. Our members bring competition to the biologic medicines market, thereby increasing access to highly innovative medical treatments to patients in Europe and around the world, and supporting the sustainability of the European healthcare systems.

About us





Biosimilar Medicines Today

Biosimilar medicines were invented in Europe 20 years ago to address the pressing need for better access to biopharmaceuticals in Europe. For example, a recent study demonstrated the inequity in access to biologic medicines for treatment of rheumatoid arthritis because lower income countries in Europe cannot afford such therapies. However even within high-income countries such as Germany and the UK, only 10-14% of patients with rheumatoid arthritis received treatment with biologic medicines. Considerable benefit awaits those patients who will gain access to treatment with biologic medicines in both low and high income EU countries thanks to the arrival of biosimilar medicines competition.

Through sophisticated new technology, our industry was able to deliver a global first with the first biosimilar medicine approved in 2006. Since that time, our industry has continued to invest substantially in new innovation, bringing the total number of biosimilar medicines available today on the European market to 20.

Read more

Our 5 Pillars

Biosimilar medicines improve access to indispensable pillars of modern treatment for millions of patients and bring better value for healthcare spending.

The biosimilar medicines industry delivers sustainability for healthcare systems and is a key partner for stakeholders.

Read more

What's new

Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health

Read more

Publications

Factsheets
View
Policy
View
Reports
View
Videos
View
Infographics
View

View all

Did you know?

Since 2006, biosimilar medicines have generated more than 400 million patient days of clinical experience.

PHOTO GALLERY

Joint 23rd Medicines For Europe and 20th IGBA Annual Conference
Joint 23rd Medicines For Europe and 20th IGBA Annual...
14-16 June 2017
Universal Access to Health 2017 - How can we contribute?
Universal Access to Health 2017 - How can we contribute?
27 April 2017
15th Biosimilar Medicines Conference
15th Biosimilar Medicines Conference
23-24 March 2017

View all